Last reviewed 2026-05-19 · How we verify

OMAPATRILAT

Phase 2 active Small molecule ✓ Verified May 2026

OMAPATRILAT is a omapatrilat drug. It is currently in Phase 2 development.

Omapatrilat works by blocking two enzymes, ACE and neprilysin, to lower blood pressure and improve heart function.

Omapatrilat is a small molecule. It has multiple synonyms, including BMS-186716 and OMAPATRILATE.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	OMAPATRILAT
Drug class	omapatrilat
Target	Angiotensin-converting enzyme, Neprilysin, Amyloid beta A4 protein
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Think of the RAAS system like a water pipe. ACE is like a valve that controls the flow of water, and neprilysin is like a pipe that helps remove excess water. By blocking these two components, omapatrilat helps reduce the amount of water in the body, which can lower blood pressure and improve heart function.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OMAPATRILAT CI brief — competitive landscape report
OMAPATRILAT updates RSS · CI watch RSS

Frequently asked questions about OMAPATRILAT

What is OMAPATRILAT?

OMAPATRILAT is a omapatrilat drug.

How does OMAPATRILAT work?

Omapatrilat works by blocking two enzymes, ACE and neprilysin, to lower blood pressure and improve heart function.

What drug class is OMAPATRILAT in?

OMAPATRILAT belongs to the omapatrilat class. See all omapatrilat drugs at /class/omapatrilat.

What development phase is OMAPATRILAT in?

OMAPATRILAT is in Phase 2.

What does OMAPATRILAT target?

OMAPATRILAT targets Angiotensin-converting enzyme, Neprilysin, Amyloid beta A4 protein and is a omapatrilat.

Drug class: All omapatrilat drugs
Target: All drugs targeting Angiotensin-converting enzyme, Neprilysin, Amyloid beta A4 protein
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing